A Phase I, Open-label, Cohort Dose Escalation Trial With BI 836858 in Patients With Refractory or Relapsed Acute Myeloid Leukemia and Patients With Acute Myeloid Leukemia in Complete Remission With High Risk to Relapse
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 09 Feb 2018
At a glance
- Drugs BI 836858 (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 07 Feb 2018 Status changed from recruiting to active, no longer recruiting.
- 05 Feb 2018 Planned End Date changed from 25 Mar 2020 to 31 May 2018.
- 05 Feb 2018 Planned primary completion date changed from 25 Mar 2020 to 27 Apr 2018.